Asapiprant for COVID-19: real-time analysis

Download Image

Post

c19early.org

Asapiprant for COVID-19

1 study with 194 patients

Serious outcome risk

Asapiprant

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Asapiprant studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−63%

Mortality (1)−63%

RCTs (1)−63%

Late (1)−63%

00.511.5+

← Asapiprant
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Asapiprant (BGE-175) is an oral, small molecule, anti-inflammatory drug that acts as a selective prostaglandin D2 receptor 1 (DP1) antagonist.


May 19 2022	Wilkerson et al., NCT04705597	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19
May 19 2022	63% higher mortality (p=0.21), 32% higher ICU admission (p=0.37), 24% higher severe cases (p=0.36), and 33% slower improvement (p=0.17). RCT 194 hospitalized COVID-19 patients showing no significant differences with asapiprant (BGE-175).